TrkA Protein — Tropomyosin Receptor Kinase A

TrkA Protein — Tropomyosin Receptor Kinase A

<div class="infobox infobox-protein">
<h3>TrkA Protein</h3>
<table>
<tr><th>Gene</th><td>[NTRK1](/genes/ntrk1) (aka TRKA)</td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/P04629" target="_blank">P04629</a></td></tr>
<tr><th>PDB Structures</th><td><a href="https://www.rcsb.org/structure/1WWA" target="_blank">1WWA</a>, <a href="https://www.rcsb.org/structure/2CT0" target="_blank">2CT0</a>, <a href="https://www.rcsb.org/structure/4GT4" target="_blank">4GT4</a></td></tr>
<tr><th>Molecular Weight</th><td>~140 kDa (full-length), ~85 kDa (mature, after processing)</td></tr>
<tr><th>Protein Length</th><td>796 amino acids (full-length)</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma membrane, endosomes, retrograde signaling endosomes</td></tr>
<tr><th>Protein Family</th><td>Receptor tyrosine kinase (RTK) family, Trk family</td></tr>
<tr><th>Chromosomal Location</th><td>1q21-q22</td></tr>
<tr><th>Ligands</th><td>NGF (Nerve Growth Factor), NT-3 (cross-reactivity at low affinity)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>
</div>

Overview

TrkA Protein — Tropomyosin Receptor Kinase A

<div class="infobox infobox-protein">
<h3>TrkA Protein</h3>
<table>
<tr><th>Gene</th><td>[NTRK1](/genes/ntrk1) (aka TRKA)</td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/P04629" target="_blank">P04629</a></td></tr>
<tr><th>PDB Structures</th><td><a href="https://www.rcsb.org/structure/1WWA" target="_blank">1WWA</a>, <a href="https://www.rcsb.org/structure/2CT0" target="_blank">2CT0</a>, <a href="https://www.rcsb.org/structure/4GT4" target="_blank">4GT4</a></td></tr>
<tr><th>Molecular Weight</th><td>~140 kDa (full-length), ~85 kDa (mature, after processing)</td></tr>
<tr><th>Protein Length</th><td>796 amino acids (full-length)</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma membrane, endosomes, retrograde signaling endosomes</td></tr>
<tr><th>Protein Family</th><td>Receptor tyrosine kinase (RTK) family, Trk family</td></tr>
<tr><th>Chromosomal Location</th><td>1q21-q22</td></tr>
<tr><th>Ligands</th><td>NGF (Nerve Growth Factor), NT-3 (cross-reactivity at low affinity)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>
</div>

Overview

TrkA (Tropomyosin Receptor Kinase A) is a high-affinity receptor tyrosine kinase for [nerve growth factor (NGF)](/entities/ngf), encoded by the [NTRK1](/genes/ntrk1) gene on chromosome 1q21-22. TrkA is a member of the Trk receptor tyrosine kinase family (TrkA, TrkB, TrkC) that mediates the cellular effects of neurotrophins — a class of growth factors essential for neuronal development, survival, and maintenance[@patapoutian2001].

In the adult brain, TrkA is predominantly expressed in basal forebrain cholinergic neurons (BFCNs), which are the primary source of acetylcholine to the hippocampus and neocortex. These cholinergic neurons undergo progressive degeneration in [Alzheimer's disease (AD)](/diseases/alzheimers-disease), and the NGF/TrkA pathway is widely recognized as a key survival signaling axis that fails in AD[@cuello1995][@cuello2020].

The NGF/TrkA signaling cascade activates three major downstream pathways — PI3K/Akt, MAPK/ERK, and PLCγ1 — that promote neuronal survival, synaptic plasticity, and gene expression. Therapeutic strategies targeting TrkA aim to preserve or enhance this signaling to protect cholinergic neurons from degeneration[@sebbe2022].

Protein Structure

Structural Architecture

TrkA is a type I transmembrane receptor with distinct extracellular and intracellular domains:

| Region | Residues | Features |
|--------|----------|----------|
| Signal peptide | 1-33 | N-terminal secretory signal |
| Extracellular domain | 34-407 | Ligand binding, cysteine-rich clusters |
| Transmembrane helix | 408-428 | Single-pass alpha-helix |
| Juxtaplasma domain | 429-445 | Dimerization interface |
| Kinase domain | 446-736 | Tyrosine kinase activity |
| C-terminal tail | 737-796 | Signaling motifs, regulatory sites |

Extracellular Domain

The extracellular region contains features critical for ligand recognition[@barbacci1995]:

Kinase Domain

The intracellular kinase domain contains:

• ATP-binding site: Critical for catalytic activity and drug targeting
• Tyrosine autophosphorylation sites: Tyr490, Tyr670, Tyr674, Tyr675 (major autophosphorylation sites)
• Activation loop: Conformational changes upon ligand binding
• Regulatory segment: Autoinhibition in the unliganded state

Dimerization and Activation

NGF binding triggers TrkA activation through[@kaplan1998]:

Signal Transduction Pathways

TrkA activates three major intracellular signaling cascades[@patapoutian2001]:

PI3K/Akt Pathway

The PI3K/Akt pathway is the primary pro-survival signaling arm of TrkA[@fahnestock2001]:

• Phosphorylation of Bad (anti-apoptotic)
• NF-κB activation
• mTORC1 activation (protein synthesis)
• GSK-3β inhibition

MAPK/ERK Pathway

The MAPK pathway promotes neuronal differentiation and survival gene expression:

• ELK1 activation → c-Fos expression
• CREB phosphorylation → BCL-2 expression
• Cell cycle regulation (differentiation vs. proliferation)

PLCγ1 Pathway

PLCγ1 generates second messengers for synaptic plasticity:

• PKC activation → synaptic protein modulation
• IP3 → Ca²⁺ release → CREB activation
• PKC → MARCKS → actin remodeling

Role in the Basal Forebrain Cholinergic System

Basal Forebrain Cholinergic Neurons

TrkA is essential for the development, maintenance, and function of basal forebrain cholinergic neurons (BFCNs)[@huang2019]:

Anatomical Location:

• Cholinergic neurons of the medial septum (MS)
• Vertical diagonal band of Broca (vDB)
• Horizontal diagonal band (HDB)
• Nucleus basalis of Meynert (NBM)

• Cortical and hippocampal acetylcholine release
• Cognitive functions (attention, learning, memory)
• Synaptic plasticity facilitation
• Cortical activation and arousal

NGF/TrkA in Alzheimer's Disease

The NGF/TrkA axis is one of the most studied therapeutic targets in AD[@cuello1995][@salehi2000]:

Evidence of Dysfunction:

• TrkA protein and mRNA levels are reduced in AD basal forebrain[@ginsberg2006]
• NGF is reduced in AD hippocampus and cortex
• TrkA signaling is impaired in AD cholinergic neurons
• Cholinergic neuron cell bodies show morphological atrophy

• Amyloid-β oligomers impair TrkA signaling
• Tau pathology disrupts axonal transport of TrkA-containing endosomes
• Neuroinflammation reduces NGF expression
• Oxidative stress impairs TrkA kinase activity

Axonal Transport

A critical feature of TrkA signaling is retrograde axonal transport:

In AD, axonal transport deficits disrupt this retrograde signaling, contributing to cholinergic dysfunction.

Therapeutic Implications

Neurotrophic Factor Therapy

Multiple approaches target the NGF/TrkA axis[@sebbe2022][@longo2020]:

| Approach | Agent | Status | Mechanism |
|----------|-------|--------|-----------|
| NGF infusion | Recombinant NGF | Phase 1/2 trials | Direct TrkA activation |
| NGF gene therapy | AAV-NGF | Preclinical | Sustained NGF expression |
| TrkA agonists | 7,8-DHF, GNF-583 | Preclinical | Small molecule activation |
| mimetic peptides | P75^NTR ligands | Research | p75^NTR modulation |
| cell-based delivery | NGF-secreting cells | Preclinical | Localized NGF delivery |

Challenges

Delivery: NGF does not cross the blood-brain barrier (BBB); requires direct CNS administration or gene therapy.

Side effects: NGF causes pain (via peripheral TrkA in nociceptors), weight loss, and sprouting of sympathetic neurons.

Tropomyosin mimetics: Small molecules that mimic NGF's TrkA-binding activity without the BBB limitation are under development.

TrkA Agonists in Development

7,8-Dihydroxyflavone (7,8-DHF): A natural TrkB agonist with some TrkA activity. Multiple preclinical studies show cognitive benefits in AD models.

GNF-583: A selective TrkA agonist with better BBB penetration than NGF.

Antibody-based agonists: Agonistic anti-TrkA antibodies are being explored to avoid p75^NTR-mediated side effects.

Cross-Pathway Connections

Related Mechanisms

• [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling) — NGF/BDNF signaling
• [PI3K/Akt Signaling](/mechanisms/pi3k-akt-signaling) — Pro-survival pathway
• [MAPK/ERK Signaling](/mechanisms/mapk-signaling) — Gene expression cascade
• [Axonal Transport Defects](/mechanisms/axonal-transport-defects) — TrkA retrograde signaling
• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms) — PLCγ1 pathway
• [Cholinergic System in AD](/mechanisms/cholinergic-system-alzheimers) — BFCN survival
• [Apoptosis Pathways](/mechanisms/apoptosis-pathway) — Akt anti-apoptotic signaling
• [Nerve Growth Factor Pathway](/mechanisms/ngf-signaling) — NGF/TrkA axis

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Cholinergic neuron degeneration
• [Congenital Insensitivity to Pain (CIP)](/diseases/congential-insensitivity-to-pain) — NTRK1 mutations
• [Diabetic Neuropathy](/diseases/diabetic-neuropathy) — NGF/TrkA dysfunction
• [Huntington's Disease](/diseases/huntingtons) — Neurotrophic support loss

Related Proteins

• [TrkB (NTRK2)](/proteins/trkb-protein) — BDNF receptor, structural homolog
• [TrkC (NTRK3)](/proteins/trkc-protein) — NT-3 receptor
• [p75^NTR (NGFR)](/proteins/p75ntr-protein) — NGF co-receptor (p75^NTR)
• [Akt1 (AKT1)](/proteins/akt1-protein) — Primary pro-survival effector
• [ERK1/2 (MAPK1/3)](/proteins/mapk1-protein) — Differentiation pathway
• [PLCγ1 (PLCG1)](/proteins/plcg1-protein) — Second messenger generation

Summary

TrkA (NTRK1) is a receptor tyrosine kinase that mediates the pro-survival and differentiation effects of NGF on neurons, particularly basal forebrain cholinergic neurons. TrkA activation triggers PI3K/Akt, MAPK/ERK, and PLCγ1 signaling cascades that promote neuronal survival, synaptic plasticity, and gene expression. In Alzheimer's disease, impaired NGF/TrkA signaling contributes to cholinergic neuron degeneration and cognitive decline. Therapeutic strategies aim to enhance TrkA signaling through NGF administration, gene therapy, or small molecule agonists.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving TrkA Protein — Tropomyosin Receptor Kinase A discovered through SciDEX knowledge graph analysis: